CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$48.69 USD
+1.19 (2.51%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $48.55 -0.14 (-0.29%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CRSP 48.69 +1.19(2.51%)
Will CRSP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRSP
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
Vertex (VRTX) Stock Outperforms Industry YTD: Here's Why
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna
Here's How to Play Vertex (VRTX) Stock After Q2 Loss, Price Dip
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
Other News for CRSP
Appeals court says the District of Columbia can proceed with its antitrust lawsuit against Amazon
First Week of April 2025 Options Trading For CRISPR Therapeutics (CRSP)
Crispr's Casgevy Launch: Promising Start, Uncertain Future
Crispr Therapeutics call volume above normal and directionally bullish
Crispr Therapeutics price target lowered by $20 at Truist, here's why